Prosecution Insights
Last updated: August 06, 2026
Application No. 18/849,000

7-KETOLITHOCHOLIC ACID INTERMEDIATE, SYNTHESIS METHOD THEREFOR, AND APPLICATION THEREOF

Non-Final OA §102§112
Filed
Sep 20, 2024
Priority
Mar 25, 2022 — CN 202210321891.5 +2 more
Examiner
SHIAO, REI TSANG
Art Unit
Tech Center
Assignee
Suzhou Entech New-Material Technology Co. Ltd.
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
2m
Est. Remaining
46%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
1643 granted / 2056 resolved
+19.9% vs TC avg
Minimal -34% lift
Without
With
+-33.9%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
54 currently pending
Career history
2082
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
29.2%
-10.8% vs TC avg
§102
8.8%
-31.2% vs TC avg
§112
30.0%
-10.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 2056 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Priority and Status of Claims 1. This application is a 371 of PCT/CN2023/083436 03/23/2023, which claims benefit of the foreign application: CHINA 202210321891.5 03/25/2022 and CHINA 202210641979.5 06/07/2022. 2. Claims 1-17 are pending in the application. Claim Rejections - 35 USC § 112 3. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. Claims 1-3 and 11-14 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112, first paragraph (pre- AIA ), because the specification does not reasonably provide enablement of the instant “a catalyst” without limitation (i.e., no named compounds). The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims. ln In re Wands, 8 USPQ2d 1400 (1988), factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph, have been described. They are: 1. the nature of the invention, 2. the state of the prior art, 3. the predictability or Iack thereof in the art, 4. the amount of direction or guidance present, 5. the presence or absence of working examples, 6. the breadth of the claims, 7. the quantity of experimentation needed, and 8. the level of the skill in the art. In the instant case: The nature of the invention The nature of the invention is a process using “a catalyst” without limitation (i.e., no named compounds), see claim 1. The state of the prior art and the predictability or Iack thereof in the art The state of the prior art is Ferrari et al. WO 2014/020024A1, it discloses a catalyst 4-methylaminopyridine, see claim 6 on page 15. The amount of direction or guidance present and the presence or absence of working examples The only direction or guidance present in the instant specification is the description of a number of “a catalyst” on pages 5-10 of the specification. There is no data present in the instant specification for the “a catalyst” without limitation (i.e., no named compound). The breadth of the claims The instant breadth of the rejected claims is broader than the disclosure, specifically, the instant “a catalyst” is without limitation (i.e., no named compound). The quantity or experimentation needed and the Ievel of skill in the art While the level of the skill in the chemical arts is high, it would require undue experimentation of one of ordinary skill in the art to resolve any “a catalyst” without limitation. There is no guidance or working examples present for constitutional any “a catalyst” without limitation for the instant invention. Incorporation of the limitation of “a catalyst” supported by specification (i.e., claim 2) into claim 1 would overcome this rejection. 4. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 102 5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim 4 is rejected under 35 U.S.C. 102(a)(2) as being anticipated by Reld et al. US 2022/0298202 A1. Applicants claim a compound of formula (I-2), i.e., PNG media_image1.png 228 388 media_image1.png Greyscale , wherein R2 is alkyl (e.g. methyl). Reld et al. ‘202 disclose of a compound 2a, i.e., PNG media_image2.png 214 324 media_image2.png Greyscale , see column 11. It clearly anticipates the instant compound of formula (I-2), wherein R2 is alkyl (i.e., methyl). 6. Claims 5-10 are neither anticipated nor rendered obvious over the record, and therefore are allowable. Claim Objections 7. Claim 4 is objected to because of the following informalities. Since claim 4 is drawn to an independent claim, therefore the definition of variable R1 shall be defined in claim 4 per se. Correction is required. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REI TSANG SHIAO whose telephone number is (571)272-0707. The examiner can normally be reached on 8:30 am-5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REI TSANG SHIAO/ Rei-tsang Shiao, Ph.D.Primary Examiner, Art Unit 1691 July 13, 2026
Read full office action

Prosecution Timeline

Sep 20, 2024
Application Filed
Jul 16, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12697317
DOSAGES AND USES OF ORNITHINE PHENYLACETATE FOR TREATING HYPERAMMONEMIA
4y 4m to grant Granted Aug 04, 2026
Patent 12697343
INTRAVENOUS ISTAROXIME FOR THE TREATMENT OF ACUTE HEART FAILURE
3y 0m to grant Granted Aug 04, 2026
Patent 12697339
COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY - ENHANCED SUPPLEMENTATION
3y 3m to grant Granted Aug 04, 2026
Patent 12691088
REACTIVATION OF mTOR IN ACUTE KIDNEY INJURY (AKI)
3y 0m to grant Granted Jul 28, 2026
Patent 12685728
ANTI-VERTIGO COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF
3y 2m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
46%
With Interview (-33.9%)
2y 0m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 2056 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month